NASDAQ:ACET - Aceto Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.79 -0.06 (-3.24 %) (As of 11/16/2018 04:00 PM ET)Previous Close$1.79Today's Range$1.76 - $1.9352-Week Range$1.53 - $11.98Volume133,190 shsAverage Volume282,397 shsMarket Capitalization$57.53 millionP/E Ratio44.75Dividend Yield2.14%Beta1.58 ProfileDiscussionAnalyst RatingsChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Aceto Corporation engages in the development, marketing, sale, and distribution of finished dosage form generic pharmaceuticals, nutraceutical products, pharmaceutical active ingredients and intermediates, specialty performance chemicals, and agricultural protection products. The company operates in three segments: Human Health, Pharmaceutical Ingredients, and Performance Chemicals. The Human Health segment supplies raw materials used in the production of nutritional and packaged dietary supplements, including vitamins, amino acids, iron compounds, and biochemicals used in pharmaceutical and nutritional preparations. This segment is also involved in developing and marketing generic pharmaceutical products. It sells its generic prescription and over-the-counter pharmaceutical products to wholesalers, chain drug stores, distributors, and mass merchandisers. The Pharmaceutical Ingredients segment offers active pharmaceutical ingredients and pharmaceutical intermediates to various generic drug companies. The Performance Chemicals segment provides specialty chemicals for use in the manufacture of plastics, surface coatings, cosmetics and personal care, textiles, and fuels and lubricants, as well as for food, flavor, paper, and film industries; dye and pigment intermediates used in the color-producing industries; and organic intermediates used in the production of agrochemicals. Its raw materials are also used in electronic parts for photo tooling, circuit boards, and production of computer chips. This segment also offers agricultural protection products comprising herbicides, fungicides, and insecticides, which control weed growth and the spread of insects and microorganisms; and sprout inhibitors for potatoes. The company serves various companies in the industrial chemical, agricultural, and human health and pharmaceutical industries primarily in the United States, Europe, and Asia. Aceto Corporation was founded in 1947 and is headquartered in Port Washington, New York. Receive ACET News and Ratings via Email Sign-up to receive the latest news and ratings for ACET and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Drugs, proprietaries, & sundries Sub-IndustryTrading Companies & Distributors SectorMedical Current SymbolNASDAQ:ACET Previous Symbol CUSIP00444610 Webwww.aceto.com Phone516-627-6000 Debt Debt-to-Equity Ratio4.08 Current Ratio1.55 Quick Ratio1.08 Price-To-Earnings Trailing P/E Ratio44.75 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$711.36 million Price / Sales0.08 Cash Flow$1.2971 per share Price / Cash1.38 Book Value$2.40 per share Price / Book0.75 Profitability EPS (Most Recent Fiscal Year)$0.04 Net Income$-316,120,000.00 Net Margins-38.57% Return on Equity-15.73% Return on Assets-3.57% Miscellaneous Employees315 Outstanding Shares30,770,000Market Cap$57.53 million OptionableOptionable Aceto (NASDAQ:ACET) Frequently Asked Questions What is Aceto's stock symbol? Aceto trades on the NASDAQ under the ticker symbol "ACET." How often does Aceto pay dividends? What is the dividend yield for Aceto? Aceto announced a quarterly dividend on Wednesday, September 12th. Investors of record on Monday, September 24th will be paid a dividend of $0.01 per share on Tuesday, October 9th. This represents a $0.04 annualized dividend and a dividend yield of 2.23%. The ex-dividend date of this dividend is Friday, September 21st. View Aceto's Dividend History. How were Aceto's earnings last quarter? Aceto Co. (NASDAQ:ACET) released its quarterly earnings data on Thursday, November, 8th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.05) by $0.54. The firm had revenue of $164.41 million for the quarter. Aceto had a negative net margin of 38.57% and a negative return on equity of 15.73%. During the same quarter in the prior year, the company posted $0.30 earnings per share. View Aceto's Earnings History. When is Aceto's next earnings date? Aceto is scheduled to release their next quarterly earnings announcement on Thursday, February 7th 2019. View Earnings Estimates for Aceto. What price target have analysts set for ACET? 2 equities research analysts have issued twelve-month price objectives for Aceto's shares. Their predictions range from $2.00 to $2.00. On average, they anticipate Aceto's stock price to reach $2.00 in the next twelve months. This suggests a possible upside of 11.7% from the stock's current price. View Analyst Price Targets for Aceto. What is the consensus analysts' recommendation for Aceto? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aceto in the last year. There are currently 2 sell ratings for the stock, resulting in a consensus recommendation of "Sell." View Analyst Ratings for Aceto. What are Wall Street analysts saying about Aceto stock? Here are some recent quotes from research analysts about Aceto stock: 1. Canaccord Genuity analysts commented, "We are pleased with the appointment of Ed Borkowski as chief financial officer, as he brings a breadth of generics knowledge and experience that will likely help Aceto’s continued transition into a human health company. We like the turnaround potential for Aceto, but believe management will need to execute for a number of quarters before generating meaningful investor interest; we maintain our BUY rating on ACET shares. Roth’s retirement has been well telegraphed in parallel to the on-boarding of William Kennally as CEO. Douglas Roth has been CFO since 2001, and was a key leader in the transformation of Aceto from specialty chemicals/API to human health. After the appointment of Bill Kennally as CEO late last year, we expected Aceto to find a thoughtful, seasoned finance leader to complement Kennally’s experience, and see Borkowski as an excellent add." (2/16/2018) 2. According to Zacks Investment Research, "Aceto Corporation markets, sells and distributes finished dosage form generics, nutraceutical products, pharmaceutical intermediates and active ingredients, agricultural protection products and specialty chemicals. The company's operating segment consists of Human Health, Pharmaceutical Ingredients and Performance Chemicals. Human Health segment supplies raw materials used in the production of nutritional and packaged dietary supplements. It markets and distributes its generic prescription and over the counter pharmaceutical products. Pharmaceutical Ingredients segment offers active pharmaceutical ingredients and pharmaceutical intermediates. Performance Chemicals segment provides specialty chemicals. It serves chemical, agricultural, human health and pharmaceutical industries. The company operates primarily in United States, Europe, and Asia. Aceto Corporation and is headquartered in Port Washington, New York. " (2/6/2018) Has Aceto been receiving favorable news coverage? Media headlines about ACET stock have trended somewhat negative on Saturday, InfoTrie Sentiment reports. The research group scores the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Aceto earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 3.0 out of 10, indicating that recent press coverage is unlikely to have an effect on the stock's share price in the near term. Are investors shorting Aceto? Aceto saw a drop in short interest in October. As of October 15th, there was short interest totalling 610,528 shares, a drop of 57.9% from the September 28th total of 1,449,517 shares. Based on an average trading volume of 1,200,490 shares, the short-interest ratio is currently 0.5 days. Currently, 2.2% of the shares of the company are sold short. View Aceto's Current Options Chain. Who are some of Aceto's key competitors? Some companies that are related to Aceto include McKesson (MCK), AmerisourceBergen (ABC), Cardinal Health (CAH), Herbalife Nutrition (HLF), Nu Skin Enterprises (NUS), PetIQ (PETQ), biOasis Technologies (BIOAF), Trxade Group (TRXD) and Medizone International (MZEI). Who are Aceto's key executives? Aceto's management team includes the folowing people: Mr. William C. Kennally III, Pres, CEO & Director (Age 63)Ms. Rebecca A. Roof, Interim Chief Financial Officer (Age 62)Mr. Steven Rogers, Sr. VP, Chief Legal Officer & Corp. Sec. (Age 57)Ms. Frances P. Scally, Sr. VP & Chief Accounting Officer (Age 51)Mr. Charles John Alaimo, Sr. VP of HR (Age 52) Who are Aceto's major shareholders? Aceto's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (10.83%), Dimensional Fund Advisors LP (7.92%), Renaissance Technologies LLC (2.40%), JPMorgan Chase & Co. (0.96%), JPMorgan Chase & Co. (0.96%) and AQR Capital Management LLC (0.73%). Company insiders that own Aceto stock include Albert L Eilender, Charles John Alaimo, Daniel B Yarosh, Douglas A Roth, Frances P Scally, Frank Debenedittis, Nicolas I Shackley, Raymond Bartone, Salvatore J Sr Guccione Sr, Satish Srinivasan, Steven Rogers and Walter J Kaczmarek III. View Institutional Ownership Trends for Aceto. Which major investors are selling Aceto stock? ACET stock was sold by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, Royce & Associates LP and Dimensional Fund Advisors LP. Company insiders that have sold Aceto company stock in the last year include Albert L Eilender, Charles John Alaimo, Frances P Scally, Frank Debenedittis, Steven Rogers and Walter J Kaczmarek III. View Insider Buying and Selling for Aceto. Which major investors are buying Aceto stock? ACET stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Renaissance Technologies LLC, JPMorgan Chase & Co., JPMorgan Chase & Co., Pacer Advisors Inc. and Janney Montgomery Scott LLC. View Insider Buying and Selling for Aceto. How do I buy shares of Aceto? Shares of ACET can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Aceto's stock price today? One share of ACET stock can currently be purchased for approximately $1.79. How big of a company is Aceto? Aceto has a market capitalization of $57.53 million and generates $711.36 million in revenue each year. The company earns $-316,120,000.00 in net income (profit) each year or $0.04 on an earnings per share basis. Aceto employs 315 workers across the globe. What is Aceto's official website? The official website for Aceto is http://www.aceto.com. How can I contact Aceto? Aceto's mailing address is 4 TRI HARBOR COURT, PORT WASHINGTON NY, 11050. The company can be reached via phone at 516-627-6000 or via email at [email protected] MarketBeat Community Rating for Aceto (NASDAQ ACET)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 185 (Vote Outperform)Underperform Votes: 202 (Vote Underperform)Total Votes: 387MarketBeat's community ratings are surveys of what our community members think about Aceto and other stocks. Vote "Outperform" if you believe ACET will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACET will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/17/2018 by MarketBeat.com StaffFeatured Article: Are Wall Street analysts' stock ratings worth following?